

## Transparency notification pursuant to Article 14 of the Law of May 2, 2007

**Leuven (Belgium) – January 18, 2018, 22:00h CET** – TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

### **Summary of the notification**

On January 16, 2018, TiGenix received a transparency notification from JPMorgan Chase & Co., following the disposal of voting securities or voting rights on January 9, 2018, after which JPMorgan Chase & Co. (through its subsidiary J.P. Morgan Securities LLC) holds 1,243,977 voting rights in TiGenix (0.45% of the total number of voting rights). As a result the participation of JPMorgan Chase & Co. has fallen below the 3% threshold.

### **Content of the notification**

*Date of the notification:* January 15, 2018.

*Reason of the notification:* disposal of voting securities or voting rights/downward crossing of the lowest threshold.

*Person subject to the notification requirement:* JPMorgan Chase & Co. (with address at c/o CT corporation, 1209 Orange Street, Wilmington, DE19801, USA), who is a parent undertaking/controlling person.

*Date on which the threshold was crossed:* January 9, 2018.

*Threshold that was crossed:* 3%.

*Denominator:* 274,287,190.

*Details of the notification:* following the acquisition of voting securities or voting rights, the number of voting rights was as follows:

- JPMorgan Chase & Co. held 0 voting rights linked to securities; and
- J.P. Morgan Securities LLC held 1,243,977 voting rights linked to securities (0.45% of the total number of voting rights based on the above denominator).

*Chain of controlled undertakings through which the holding is effectively held:* J.P. Morgan Securities LLC is controlled (100%) by J.P. Morgan Broker - Dealer Holdings Inc., which is controlled (100%) by JPMorgan Chase Holdings LLC, which is controlled (100%) by JPMorgan Chase & Co.

*Additional information:* this position refers to third party shares where rights of use are held.

# TIGENIX

This press release and the above-mentioned transparency notification can be consulted on our website:

- press release: <http://tigenix.com/news-media/press-releases/>
- notifications: <http://tigenix.com/investors/share-information/shareholder-overview>

## **For more information:**

TiGenix  
Claudia Jiménez  
Senior Director Investor Relations and Communications  
Tel: +34918049264  
[Claudia.jimenez@tigenix.com](mailto:Claudia.jimenez@tigenix.com)

## **About TiGenix**

*TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced biopharmaceutical company developing novel therapies for serious medical conditions by exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells.*

*TiGenix' lead product, Cx601, has successfully completed a European Phase III clinical trial for the treatment of complex perianal fistulas - a severe, debilitating complication of Crohn's disease. Cx601 received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) and a global Phase III trial intended to support a future U.S. Biologic License Application (BLA) started in 2017. TiGenix has entered into a licensing agreement with Takeda, a global pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to develop and commercialize Cx601 for complex perianal fistulas outside the U.S. TiGenix' second adipose-derived product, Cx611, is undergoing a Phase I/II trial in severe sepsis – a major cause of mortality in the developed world. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain) and Cambridge, MA (USA). For more information, please visit <http://www.tigenix.com>.*